ArticleCerebellum (London, England)2024
Global and Regional Brain Grey and White Matter Morphometry Alterations in Type 1, 2, and 3 Spinocerebellar Ataxias (SCAs) Patients.
Article in Cerebellum (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioinformatic Analyses of the Ataxin-2 Family Since Algae Emphasize Its Small Isoforms, Large Chimerisms, and the Importance of Human Exon 1B as Target of Therapies to Prevent Neurodegeneration.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Spinocerebellar ataxias (SCAs) types 1, 2, and 3 are the most common subtypes of SCAs. However, the atrophy patterns of these three subtypes still need to be fully clarified. In this study, a total of 130 genetically confirmed SCA patients (SCA1: n = 16; SCA2: n = 13; symptomatic SCA3: n = 76; pre-symptomatic SCA3: n = 25) along with 65 age- and sex-matched healthy controls (HCs) were enrolled. MR volumetric analysis was used to explore the different atrophied patterns in these three SCA subtypes and the associations between significant morphometry alterations and clinical variables were further analyzed. Compared with HCs, the global brain grey matter (GM) of the three SCA subtypes and white matter (WM) volumes of the SCA2 and SCA3 were significantly reduced. SCA2 had significantly more severe GM volume atrophy than symptomatic SCA3. For local GM and WM volumes, all three subtypes of SCA have significant atrophy in infra- and supratentorial areas than HCs. The pre-symptomatic SCA3 patients had already demonstrated substantial WM atrophy. The SCAs subgroup comparisons showed that compared with symptomatic SCA3, SCA1 and SCA2 demonstrated more severe atrophy in regions of the cerebral and cerebellum, but symptomatic SCA3 had significantly atrophied bilateral lenticular nuclei. Besides, no significant difference was found in the local GM or WM volume between SCA1 and SCA2. Furthermore, some affected GM and WM regions, especially the damaged cerebellar peduncles, showed significant correlations with disease duration and severity in SCA1 and symptomatic SCA3. Our research results indicate differences in MRI brain injury patterns among common SCA subtypes, which might shed light on the deeper understanding of the pathophysiological mechanisms of SCAs.
Indexed as
Identifiers
39643850What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.